| Literature DB >> 28718836 |
Wei Tian1, Zixin Deng2, Kui Hong3.
Abstract
Ophiobolins (Ophs) are a group of tricarbocyclic sesterterpenoids whose structures contain a tricyclic 5-8-5 carbotricyclic skeleton. Thus far, 49 natural Ophs have been reported and assigned into A-W subgroups in order of discovery. While these sesterterpenoids were first characterized as highly effective phytotoxins, later investigations demonstrated that they display a broad spectrum of biological and pharmacological characteristics such as phytotoxic, antimicrobial, nematocidal, cytotoxic, anti-influenza and inflammation-promoting activities. These bioactive molecules are promising drug candidates due to the developments of their anti-proliferative activities against a vast number of cancer cell lines, multidrug resistance (MDR) cells and cancer stem cells (CSCs). Despite numerous studies on the biological functions of Ophs, their pharmacological mechanism still requires further research. This review summarizes the chemical structures, sources, and biological activities of the oph family and discusses its mechanisms and structure-activity relationship to lay the foundation for the future developments and applications of these promising molecules.Entities:
Keywords: bioactivities; mechanisms; ophiobolins; source; structure–activity relationship
Mesh:
Substances:
Year: 2017 PMID: 28718836 PMCID: PMC5532671 DOI: 10.3390/md15070229
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Carbon skeleton of Ophs.
Figure 2Structures of Ophs. * The compounds from marine-derived fungi. All assigned stereocenters of the structures of Ophs have been drawn in Figure 2. However, there are still some undepicted stereochemistry of structures in Figure 2 because the stereochemistry in the original literature was not supplied.
Sources of Ophs.
| Number | Compound | Source | Reference | Source | Reference |
|---|---|---|---|---|---|
| Ophiobolin A | [ | [ | |||
| [ | [ | ||||
| 6-epi-ophiobolin A | [ | [ | |||
| [ | [ | ||||
| [ | [ | ||||
| 3-anhydroophiobolin A | [ | [ | |||
| [ | - | - | |||
| 3-anhydro-6-epi-ophiobolin A | [ | [ | |||
| [ | [ | ||||
| [ | - | - | |||
| 3-anhydro-6-hydroxy-Ophiobolin A | [ | - | - | ||
| Ophiobolin A lactone | [ | - | - | ||
| Ophiobolin B | [ | [ | |||
| [ | [ | ||||
| [ | - | - | |||
| 3-anhydro-6-epi-ophiobolin B | [ | - | - | ||
| Ophiobolin B lactone | [ | - | - | ||
| Ophiobolin C | [ | [ | |||
| [ | [ | ||||
| [ | [ | ||||
| 6-epi-ophiobolin C | [ | [ | |||
| 18-dihydroophiobolin C | [ | - | - | ||
| Ophiobolin D | [ | - | - | ||
| Ophiobolin E | [ | - | - | ||
| Ophiobolin F | [ | [ | |||
| Ophiobolin G | [ | [ | |||
| [ | - | - | |||
| 6-epi-ophiobolin G | [ | [ | |||
| [ | [ | ||||
| [ | - | - | |||
| (6a)-21,21-O-dihydroophiobolin G | [ | [ | |||
| (6a)-21-deoxyophiobolin G | [ | - | - | ||
| 3-anhydro-21-deoxyophiobolin G | [ | - | - | ||
| (6a)-18,19,21,21-Otetrahydro-18,19-dihydroxy-ophiobolin G | [ | - | - | ||
| (6a)-16,17-dihydro-21-deoxy-ophiobolin G | [ | [ | |||
| Ophiobolin H | [ | [ | |||
| [ | [ | ||||
| (5a,6a)-ophiobolin H | [ | - | - | ||
| 5-O-methylophiobolin H | [ | - | - | ||
| (5a,6a)-5-O-methylophiobolin H | [ | - | - | ||
| Ophiobolin I | [ | [ | |||
| [ | [ | ||||
| [ | [ | ||||
| [ | - | - | |||
| 6-epi-ophiobolin I | [ | - | - | ||
| 25-Hydroxyophiobolin I | [ | [ | |||
| Ophiobolin J | [ | [ | |||
| 8-epi-ophiobolin J | [ | - | - | ||
| 8-deoxyophiobolin J | [ | - | - | ||
| Ophiobolin K | [ | [ | |||
| [ | [ | ||||
| [ | [ | ||||
| 6-epi-Ophiobolin K | [ | [ | |||
| [ | [ | ||||
| [ | [ | ||||
| [ | - | - | |||
| Ophiobolin L | [ | - | - | ||
| 6-epi-ophiobolin L | [ | - | - | ||
| Ophiobolin M | [ | - | - | ||
| 6-epi-ophiobolin M | [ | - | - | ||
| 6-epi-ophiobolin N | [ | [ | |||
| Ophiobolin O | [ | - | - | ||
| 6-epi-ophiobolin O | [ | - | - | ||
| Ophiobolin P-T | [ | - | - | ||
| Ophiobolin U-W | [ | [ |
The titles of columns 3 and 4 were the same status as columns 5 and 6, respectively. Drechslera oryzae 1, Helminthosporium oryzae 3 are reclassified in Bipolaris oryzae, Taxonomy ID: 101162; Cochliobolus heterostrophus 2 is reclassified in Bipolaris maydis, Taxonomy ID: 5016; Emericella variecolor 4 is reclassified in Aspergillus stellatus, Taxonomy ID: 1549217; Polyangium cellulosum 5 is reclassified in Sorangium cellulosum, Taxonomy ID: 56; Penicillium patulum 6 is reclassified in Penicillium griseofulvum, Taxonomy ID: 5078.
Phytotoxic activities of Ophs by the leaf-wounding assay.
| Plant | 1 | 2 | 3 | 4 | 7 | 10 | 27 | 29 |
|---|---|---|---|---|---|---|---|---|
| Barley | >4.5 a | 3.0–4.5 a | 3.0–4.5 a | <0.5 a | 0.5–1.5 a | NA | 0.5–1.5 a | NA |
| Cabbage | 0–2 *, b | >2 *, b | >0 *, b | >0 *, b | >0 *, b | NA | >0 *, b | NA |
| Cocklebur | 0.5–1.5 a | 1.5–3.0 a | 1.5–3.0 a | <0.5 a | 0.5–1.5 a | NA | 0.5–1.5 a | NA |
| Corn | 3.0–4.5 a | 1.5–3.0 a | 3.0–4.5 a | 0.5–1.5 a | 0.5–1.5 a | NA | 0.5–1.5 a | NA |
| >2 *, b | 0–2 *, b | >2 *, b | >0 *, b | >0 *, b | NA | N *, b | NA | |
| 2–3 c | >3 c | NA | NA | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c | |
| Goose grass | 1.5–3.0 a | 3.0–4.5 a | 1.5–3.0 a | 1.5–3.0 a | 1.5–3.0 a | NA | 1.5–3.0 a | NA |
| Grain sorghum | 3.0–4.5 a | 1.5–3.0 a | 3.0–4.5 a | 1.5–3.0 a | 3.0–4.5 a | NA | 0.5–1.5 a | NA |
| Johnson grass | 2–3 c | >3 c | NA | NA | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c |
| Rice | 3.0–4.5 a | 1.5–3.0 a | 3.0–4.5 a | 0.5–1.5 a | 0.5–1.5 a | NA | 0.5–1.5 a | 3.0–4.5 a |
| >0 *, b | 0–2 *, b | 0–2 *, b | >0 *, b | 0–2 *, b | NA | >0 *, b | NA | |
| Sorghum | 2–3 c | 2–3 c | NA | NA | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c | 0.5–2.0 c |
| Soybean | 1.5–3.0 a | 1.5–3.0 a | 1.5–3.0 a | <0.5 a | 1.5–3.0 a | NA | 0.5–1.5 a | NA |
| Tobacco | >0 *, b | >0 *, b | >0 *, b | N b | >0 *, b | NA | >0 *, b | NA |
| Velvet-leaf | 0.5–1.5 a | <0.5 a | 1.5–3.0 a | <0.5 a | <0.5 a | NA | 0.5–1.5 a | NA |
The phytotoxic activities are characterized by necrosis diameter, mm; * at the concentration of 1.2 × 103 μM; other unmarked, 1.0 × 103 μM; N, no phytotoxic activity; NA, not available; a, b, c, refer to References [15], [14], [13], respectively.
Antibacterial activities of Ophs.
| Number | Antibacterial Activity | ||||||
|---|---|---|---|---|---|---|---|
| MRSA | BCG | ||||||
| >62 a | 62/7–12 a | NA | 62/3–6 a | NA | NA | NA | |
| NA | >100 b | >100 b | NA | >100 b | >100 b | NA | |
| NA | 31 b | 31 b | NA | 31 b | 31 b | NA | |
| >62 a | 62/3–6 a | NA | >62 a | NA | NA | NA | |
| >2.7 × 103 c | NA | NA | NA | 136/10 c | NA | NA | |
| NA | NA | >250d | NA | >250 d | 125/NR d | 68/NR e | |
| NA | NA | >250 d | NA | >250 d | 125/NR d | NA | |
| >2.6 × 103 c | >1.6 × 103 f | NA | NA | 682/16 c | NA | NA | |
| 1.6 × 103/10 f | >1.6 × 103 f | NA | NA | NA | NA | NA | |
| >63 a | >63 a | NA | 63/3–6 a | NA | NA | NA | |
| NA | NA | NA | NA | NA | 64/NR e | 33/NR e | |
| NA | NA | 125/NR d | NA | 125/NR d | >250 d | 260/NR e | |
| >60.a | >60 a | NA | 60/3–6 a | NA | NA | NA | |
| >60 a | 60/>12 a | NA | >60 a | NA | NA | NA | |
| NA | NA | 31/NR d | NA | 62/NR d | >250 d | NA | |
| NA | NA | >250 d | NA | >250 d | >250 d | NA | |
| NA | NA | 16/NR d | NA | 31/NR d | 31/NR d | NA | |
| 1.6 × 103/15 f | 1.6 × 103/10 f | NA | NA | NA | NA | NA | |
The antibacterial activities are assessed on concentration/inhibitory diameter, μM/mm; * indicate compound 12, 16, 18, 44 and 45 showed no activity against the pathogen at 1.7, 1.8, 1.7, 1.6, 1.6 × 103 μM, respectively; E. coli: Escherichia coli; S. aureus: Staphylococcus aureus; M. intracellulare: Mycobacterium intracellulare; B. subtilis: Bacillus subtilis; MRSA: methicillin-resistant Staphylococcus aureus; BCG: Bacille Calmette-Guerin; M. smegmatis: Mycobacterium smegmatis. NA, not available; NR, using MIC, no reported inhibitory diameter; a, b, c, d, e, f, refer to references [30], [38], [44], [29], [27], and [43], respectively.
Nematocidal activity of Ophs.
| Number | Species | Concentration (LD50, μM) | Reference |
|---|---|---|---|
| 5 | [ | ||
| 130 | [ | ||
| 25 | [ | ||
| 26 | [ | ||
| 13 | [ | ||
| >260 | [ | ||
| 9.6 | [ | ||
| 13 | [ | ||
| 130 | [ |
Cytotoxic activities of Ophs.
| Number | Cell Line | IC50 (μM) | Reference | Cell Line | IC50 (μM) | Reference |
|---|---|---|---|---|---|---|
| CLL | 1 × 10−3 * | [ | P388 | 0.06 | [ | |
| HUVECs | 0.08 | [ | MNA | <0.12 | [ | |
| HT-29 | 0.12 | [ | A549 | 0.12, 0.42 ± 0.01 | [ | |
| FFL | 0.12 | [ | PK-15 | 0.12–0.24 | [ | |
| OVCAR3 | 0.28 | [ | B16F10 | 0.29 ± 0.05 | [ | |
| L1210 | 0.3 | [ | SKMEL28 | 0.37 ± 0.03 | [ | |
| RPMI8226 | 0.4 | [ | Hs683 | 0.62 ± 0.04 | [ | |
| MM1R | 0.7 | [ | U266B1 | 0.7 | [ | |
| U373-MG | 0.87 ± 0.01 | [ | Jurkat | 1.0 | [ | |
| A2780 | 1.2 | [ | RD | 1–2, 1.3 | [ | |
| KB 3-1 | 1.4 | [ | RH30 | 1.5 | [ | |
| MDAMB-231 | 1.9, 0.7 | [ | T98G | 1.9 ± 0.2 | [ | |
| PC3 | 2.5 | [ | U2OS | 2.8 | [ | |
| GL19 | 3.7 ± 1.4 | [ | U-87MG | 3.8 | [ | |
| MCF-7 | 4.3; 4.0 | [ | LLC-GA5-COL150 | 7.9 ± 0.40 | [ | |
| hPBMC | 21 | [ | HeLa | 62; 4.5 | [ | |
| KB | 78 | [ | - | - | - | |
| HeLa | 14 | [ | KB | 22 | [ | |
| HeLa | 10 | [ | KB | 12 | [ | |
| K562 | 40 ± 5.5 | [ | HepG 2 | 56 ± 3.8 | [ | |
| CLL | Inactive * | [ | - | - | - | |
| B16F10 | 22 ± 3 | [ | SKMEL28 | 27 ± 0.4 | [ | |
| A549 | 30 ± 1 | [ | Hs683 | 30 ± 3 | [ | |
| K562 | 36 ± 4.4 | [ | HepG 2 | 47 ± 4.8 | [ | |
| CLL | Inactive * | [ | - | - | - | |
| K562 | 4.1 ± 0.50 | [ | HepG2 | 6.5 ± 0.34 | [ | |
| CLL | 2 × 10−3 * | [ | - | - | - | |
| CLL | 8 × 10−3 * | [ | - | - | - | |
| P388 | 25 | [ | - | - | - | |
| HepG2 | 0.37 ± 0.03 | [ | KB | 1.4 ± 0.06 | [ | |
| CLL | Inactive * | [ | - | - | ||
| HepG2 | 2.2 ± 0.18 | [ | KB | 4.0 ± 0.22 | [ | |
| L5178Y | >27 | [ | - | - | - | |
| L5178Y | >25 | [ | - | - | - | |
| P388 | 106 | [ | CLL | Inactive * | [ | |
| L5178Y | >25 | [ | - | - | - | |
| HeLa | 0.25 | [ | HUVECs | >1 | [ | |
| KB | 2.3 | [ | OVCAR3 | 71 | [ | |
| CLL | 4 × 10−3 * | [ | ACHN | 0.27 | [ | |
| HCT116 | 0.33 | [ | T-47D | 0.35 | [ | |
| P388/ADR | 0.36 | [ | TK-10 | 0.51 | [ | |
| MCF-7 | 0.51 | [ | P388 | 0.51; 13 | [ | |
| MDA-MB-231 | 0.57 | [ | NCI-H460 | 0.57 | [ | |
| HOP18 | 0.65 | [ | - | - | - | |
| HepG2 | 1.9 ± 0.11 | [ | TK-10 | 3 | [ | |
| MCF-7 | 3 | [ | KB | 4.7 ± 0.72 | [ | |
| P388 | 25 | [ | CLL | Inactive * | [ | |
| CLL | Inactive * | [ | - | - | - | |
| P388 | 4.7 | [ | MCF-7 | 13 ± 1.3 | [ | |
| HUVEC | 85 ± 12 | [ | DU145 | 16 ± 2.7 | [ | |
| NCI-H460 | 14 ± 1.0 | [ | - | - | - | |
| P388 | 9.3 | [ | - | - | - | |
| HepG2 | 1.5 ± 0.10 | [ | KB | 6.2 ± 0.25 | [ | |
| HepG2 | 1.3 ± 0.12 | [ | KB | 2.4 ± 0.21 | [ | |
| HepG2 | 1.2 ± 0.08 | [ | KB | 2.9 ± 0.28 | [ | |
| HepG2 | 1.4 ± 0.08 | [ | KB | 4.9 ± 0.32 | [ | |
| HepG2 | 0.24 ± 0.02 | [ | KB | 3.0 ± 0.24 | [ |
The cytotoxic activities of Ophs with the cell lines in ascending order of the IC50 values by MTT assay; * LC50 value, cytotoxic activities test by CellTiter-Glo® assay; (1) Human cancer cell lines: brain cancer cells, Hs683; breast carcinoma cells, MCF-7, MDA-MB-231 and T-47D; cervical carcinoma cells, HeLa; colon carcinoma cells, HCT116 and HT-29; GBM cells, GL19, U373-MG, T98G and U-87MG; haematological cancer cells, Jurkat, MM1R, RPMI8226, U266B1; hepatocarcinoma cells, HepG2; large cell lung carcinoma cells, NCI-H460; leukemia cells, CLL, K562 and L1210; lung carcinoma cells, A549, NCI-H460 and HOP18; melanoma cells, B16F10 and SKMEL28; nasopharyngeal carcinoma cells, KB and KB 3-1; osteosarcoma cells, U2OS; ovarian cancer cells A2780 and OVCAR3; prostate cancer cells, DU145 and PC3; renal carcinoma cells, ACHN; rhabdomyosarcoma cancer cells, RD and RH30; (2) Human normal cell lines: hPBMC, peripheral blood mononuclear cells; HUVEC, human umbilical vein endothelial cell line; (3) Other mammalian cell lines: adriamycin resistant cells, P388/ADR; feline fetus lung cells, FFL; mouse leukemia cells, P388; murine lymphoma cells, L5178Y; murine neuroblastoma cells, MNA; porcine kidney cells, PK-15; (4) LLC-GA5-COL150 cells, cells transfected with human multidrug resistance 1 (MDR1) cDNA encoding P-gp.
Cell death induced by ophiobolins.
| Cell Death | Observations | Ophs | Cell Lines | Reference |
|---|---|---|---|---|
| Apoptosis | Cell soma shrinkage, chromatin condensation, typical apotptotic DNA ladder | L1210 | [ | |
| Changes of caspase 3/7 | MDA-MB-231 | [ | ||
| * AV+/PI−, AV+/PI+ and PARP increase | RD, RH30 | [ | ||
| AV+/PI+ increase | MDA-MB-231, MCF-7 HeLa | [ | ||
| AV+, Caspase-3 activation | CLL | [ | ||
| Bcl-2 decrease | K562 | [ | ||
| Bcl-2 decrease | MCF-7 | [ | ||
| Necrosis | AV−/PI+ increase | KB 3-1, U2OS, U-87 MG | [ | |
| Paraptosis | BKCa decreasing, cytoplasmic vacuolization and mitochondrial swelling | U373-MG, GL19 | [ |
* Annexin V binds phosphatidyl serine and can be used as a probe for cell death via an apoptotic pathway. Combination of Annexin V and PI (which stains the DNA of cells with a permeable membrane, i.e., necrotic cells) can determine early apoptotic cells which are Annexin V positive and PI negative (AV+/PI−) [64].